

## Disclosures

### Personal Commercial (6)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Consultant Fees/Honoraria	Significant (>= \$5,000)	Arrhythmias and Clinical EP Other
Abbott Laboratories (SJM)	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP Other
Biosense Webster Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP
Biotronik	Consultant Fees/Honoraria	Significant (>= \$5,000)	Arrhythmias and Clinical EP
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	Arrhythmias and Clinical EP
Medtronic	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (4)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2024	endocarditis	Defendant † no commercial funding	Patient developed endocarditis that was not diagnosed on initial consultation by cardiologist. Consultant, case ongoing.	Modest (< \$5,000)
2023	Atrial esophageal fistula	Defendant † no commercial support	3 weeks post ablation developed neurologic symptoms and found to have atrial esophageal fistula. Consultant, no deposition or trial. Case settled.	Modest (< \$5,000)
2021	cerebral vascular accident	Plaintiff † no commercial funding	suffered CVA off anticoagulation x 2 weeks. History of paroxysmal atrial fibrillation, s/p ablation. Consultant, no deposition or trial.	Modest (< \$5,000)
2021	Cardiomyopathy and bradycardia	Defendant † no commercial funding	patient with recurrent syncope and cardiomyopathy suffered cardiac arrest	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 12/4/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 12/4/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 12/4/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 3/18/2024

---

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.